A new multi-institution study spearheaded by researchers at Florida State University and the University of California, Los Angeles suggests a tiny protein could play a major role in combating heart failure related to Duchenne muscular dystrophy (DMD), the most common lethal genetic disorder among children.
In collaboration with scientists from across the nation, FSU researchers found that increased levels of the protein sarcospan improve cardiac function by reinforcing cardiac cell membranes, which become feeble in patients with DMD.
Their findings were published in the journal JCI Insight.
The condition, which typically afflicts young boys, is caused by a mutation that prevents the body from producing dystrophin, a protein crucial to the health of skeletal, respiratory and cardiac muscles. Advances in treatment for certain types of DMD-related muscle degradation have helped to prolong patients’ lifespans. However, as DMD patients age, their heart function declines dramatically.
“Patients typically live to 20 or 30 years of age,” said lead author Michelle Parvatiyar, an assistant professor in the Department of Nutrition, Food and Exercise Sciences in FSU’s College of Human Sciences. “There have been important improvements in respiratory care, which used to be what a majority of patients would succumb to. Now, in their 20s and 30s, they’re often succumbing to cardiomyopathy. The heart is functioning with a major component of the cell membrane missing. Over time, it wears out.”
The study was part of continued efforts by UCLA biologist Rachelle H. Crosbie, the study’s corresponding author, who previously identified sarcospan as a protein that could improve mechanical support in skeletal cell membranes lacking dystrophin. Her finding buoyed DMD researchers and affirmed sarcospan’s potential as an effective tool in the fight against the condition.
“But nobody had really looked at how increasing the levels of this protein might affect the heart,” Parvatiyar said.
Using a unique mouse model with a dearth of dystrophin, Parvatiyar and her collaborators did just that.
In their study, the team found that while it’s is not a like-for-like replacement for dystrophin, an overexpression of sarcospan in cardiac cells seems to do the job of stabilizing cell membranes. Even under stress, researchers found, sarcospan overexpression was able to improve the membrane defect in dystrophin-deficient cells.
“Sarcospan doesn’t quite do the job of dystrophin, but it acts as a glue to stabilize the membrane and hold protein complexes together when dystrophin is lacking,” said Parvatiyar, explaining a concept developed by Crosbie.
Cardiac measurements confirmed that sarcospan does protect the cell membrane even when the heart is placed under stress. Study co-author and FSU College of Medicine Associate Professor Jose Pinto performed the measurements, along with FSU graduate student Karissa Dieseldorff Jones and University of Miami Miller School of Medicine research assistant Rosemeire Takeuchi Kanashiro.
In addition to serving as a kind of stabilizing glue, researchers said sarcospan could also act as a scaffold that supports other essential proteins at the cell membrane. That function could allow sarcospan to carry mini versions of dystrophin — which, in its normal state, has a long and unwieldy genetic code — to the edges of cardiac cells, where they could buttress the fragile membranes.
“The idea is that you could administer the sarcospan and the dystrophin at the same time, and the sarcospan could facilitate mini dystrophin localizing to the cell membrane and help hold those complexes in place,” Parvatiyar said.
Sarcospan’s two possible functions could augment existing DMD treatments, Parvatiyar said, or they could give rise to novel therapies that fortify weakened cardiac cell membranes and improve the quality of life for people with DMD.
In her previous position at UCLA, Parvatiyar had frequent interactions with DMD patients and their families. She said these interactions, and the unshakeable hope she’s witnessed in those suffering from DMD, continue to drive her and her colleagues in the search for new ways to combat this debilitating condition.
“Those were the first times in my life I’d ever had someone come up to me and thank me for my work,” she said. “Sometimes you can feel removed from it in the laboratory day after day. You see incremental progress. But to see people who are really yearning for help is motivating. Their positivity is incredibly inspiring.”
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Team Ethan: Meet the 10-year-old Decatur boy serving as MDA's National Ambassadoron March 21, 2020 at 10:00 pm
Like many young children, summer camp, from water tubing to zip lining to water sliding, represents Ethan LyBrand’s favorite time of year. It is where the 10-year-old Decatur boy, despite his battle ...
- Capricor Therapeutics' (CAPR) CEO Linda Marban on Q4 2019 Results - Earnings Call Transcripton March 18, 2020 at 5:21 pm
All of us at Capricor are driven to achieve our goal of bringing our lead product candidate, CAP-1002 to patients for the treatment of Duchenne Muscular Dystrophy, and we are committed to expanding ...
- Catabasis Pharmaceuticals to Present During the Muscular Dystrophy Association Virtual Clinical Trials Sessionon March 18, 2020 at 5:18 pm
Catabasis Pharmaceuticals to Present During the Muscular Dystrophy Association Virtual Clinical Trials Session ...
- For People With Compromised Immune Systems, COVID-19 Is Seriouson March 18, 2020 at 1:25 pm
Michael Norton is one of those Americans. He's 32 years old, and he was born with Duchenne muscular dystrophy. That means he has to have a ventilator with him at all times to give him oxygen. To stay ...
- Dr. Crystal Proud | Health Care Heroeson March 16, 2020 at 11:44 pm
“Now we have medicines that effectively deliver that missing gene to a child’s body." Proud has also participated in clinical trials for Duchenne muscular dystrophy, a disease that causes an inability ...
- Several Lower Extremity MR Biomarkers Predict Future Ambulatory Function in Patients With Duchenne Muscular Dystrophyon March 16, 2020 at 9:30 am
Researchers investigated the potential of lower extremity magnetic resonance biomarkers to serve as endpoints in clinical trials of therapeutics for Duchenne muscular dystrophy. Several magnetic ...
- What Living With Duchenne Muscular Dystrophy Has Taught Meon March 16, 2020 at 12:10 am
For the past 23 years, I have battled a rare neuromuscular disease named Duchenne muscular dystrophy (DMD). It causes my muscles to waste away over time, so I use a power wheelchair and have little ...
- A signaling hub of insulin receptor, dystrophin glycoprotein complex and plakoglobin regulates muscle sizeon March 13, 2020 at 3:21 am
Insulin receptor signaling governs central physiological functions related to cell growth and metabolism. Here the authors use protein complex purification and super-resolution microscopy to show that ...
- Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skippingon March 13, 2020 at 3:15 am
Expression of Cas9 and gRNA from viral vectors in vivo may cause off-target activity. Here the authors present NanoMEDIC, which uses nanovesicles to transiently deliver editing machinery to ...
- Parent Project Muscular Dystrophy Leads Duchenne Community to Nation's Capital for Annual Advocacy Conferenceon March 10, 2020 at 6:05 pm
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), heads to Washington, D.C., March 8–10, for their annual Advocacy ...
via Bing News